Age, gender and efflux transporter activity influence imatinib efficacy in chronic myeloid leukemia patients

Leuk Res. 2019 Jul:82:33-35. doi: 10.1016/j.leukres.2019.05.012. Epub 2019 May 25.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • ATP Binding Cassette Transporter, Subfamily B, Member 1 / genetics
  • ATP Binding Cassette Transporter, Subfamily B, Member 1 / metabolism*
  • Adult
  • Age Factors
  • Antineoplastic Agents / metabolism
  • Antineoplastic Agents / therapeutic use*
  • B-Lymphocytes / drug effects*
  • B-Lymphocytes / metabolism
  • B-Lymphocytes / pathology
  • Biological Transport
  • Biomarkers, Tumor / genetics
  • Biomarkers, Tumor / metabolism
  • Female
  • Humans
  • Imatinib Mesylate / metabolism
  • Imatinib Mesylate / therapeutic use*
  • K562 Cells
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / metabolism
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology
  • Male
  • Middle Aged
  • Primary Cell Culture
  • Progesterone / pharmacology
  • Proto-Oncogene Proteins c-abl / genetics
  • Proto-Oncogene Proteins c-abl / metabolism
  • Sex Factors
  • Treatment Outcome

Substances

  • ATP Binding Cassette Transporter, Subfamily B, Member 1
  • Antineoplastic Agents
  • Biomarkers, Tumor
  • Progesterone
  • Imatinib Mesylate
  • ABL1 protein, human
  • Proto-Oncogene Proteins c-abl